A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Clinical trial NCT04280081 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04280081
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-16
- Primary completion
- 2021-03-25
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.